SOTIO Biotech
SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. Clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, SOT101, currently being tested in phase II clinical trials. Three programs will enter phase I soon, including SOT201, and IL-15-based immunocytokine, BOXR1030, a GPC3-targeted CAR-T based on proprietary technology designed to improve on the efficacy of CAR T therapies in the tumor microenvironment and SOT102, a next generation Claudin18.2-targeted antibody-drug conjugate (ADC).